Finn F M, Johns P A, Nishi N, Hofmann K
J Biol Chem. 1976 Jun 25;251(12):3576-85.
The ability of three analogs of ACTH1-24 ([Gln5, Phe9] ACTH1-24, [Gln5, Ala9[Acth1-24, and [Gln5, Lys8, Phe9[ ACTH1-24) embodying tryptophan substitutions to activate the adenylate cyclase system of a bovine adrenal plasma membrane preparation was compared to the effect of the analogs on adenosine 3':5'-monophosphate (cyclic AMP) accumulation and steroidogenesis in viable bovine adrenocortical cells. The results were not comparable. Whereas the analogs antagonized the ACTH1-24-activated membrane cyclase they stimulated cyclic AMP accumulation as well as steroid production of the cells. None of the analogs inhibited steroidogenesis of ACTH1-24-stimulated cells, but two of them, at very high dose levels, inhibited cyclic AMP production. The ability of the analogs to stimulate steroidogenesis of the adrenal cells half-maximally decreased in the order tryptophan greater than phenylalanine greater than alanine, indicating that the aromaticity of the indole ring of tryptophan is necessary for maximal interaction between hormone and receptor. Both the absolute and relative steroidogenic potencies were the same for several analogs when assayed with rat adrenal cells. Although only a small fraction of the cell's potential to produce cyclic AMP was necessary to induce maximum steroid production, the relative activities of a series of analogs were the same for steroidogenesis as for cyclic AMP accumulation. Furthermore, the concentration of cyclic AMP necessary for full steroidogenesis was practically identical for a series of peptides that differed widely in potency. These findings support the postulate that cyclic AMP accumulation and steroidogenesis in adrenocortical cells are coupled processes. The differential behavior of bovine adrenal plasma membranes and bovine adrenocortical cells toward ACTH analogs indicates that structure-function studies using cyclase assays may not reflect events that take place in the intact adrenal or in cell preparations derived therefrom.
将三种含色氨酸替代的促肾上腺皮质激素1 - 24类似物([谷氨酰胺5,苯丙氨酸9]促肾上腺皮质激素1 - 24、[谷氨酰胺5,丙氨酸9]促肾上腺皮质激素1 - 24和[谷氨酰胺5,赖氨酸8,苯丙氨酸9]促肾上腺皮质激素1 - 24)激活牛肾上腺质膜制剂腺苷酸环化酶系统的能力,与这些类似物对活牛肾上腺皮质细胞中3':5'-单磷酸腺苷(环磷酸腺苷)积累和类固醇生成的影响进行了比较。结果并不具有可比性。虽然这些类似物拮抗促肾上腺皮质激素1 - 24激活的膜环化酶,但它们刺激了细胞中环磷酸腺苷的积累以及类固醇的产生。没有一种类似物抑制促肾上腺皮质激素1 - 24刺激的细胞的类固醇生成,但其中两种在非常高的剂量水平下抑制了环磷酸腺苷的产生。这些类似物刺激肾上腺细胞类固醇生成的能力半数最大效应降低的顺序为色氨酸大于苯丙氨酸大于丙氨酸,这表明色氨酸吲哚环的芳香性对于激素与受体之间的最大相互作用是必要的。当用大鼠肾上腺细胞进行测定时,几种类似物的绝对和相对类固醇生成效力是相同的。虽然诱导最大类固醇产生仅需要细胞产生环磷酸腺苷潜力的一小部分,但一系列类似物在类固醇生成方面的相对活性与环磷酸腺苷积累方面的相对活性相同。此外,对于一系列效力差异很大的肽,完全类固醇生成所需的环磷酸腺苷浓度实际上是相同的。这些发现支持了肾上腺皮质细胞中环磷酸腺苷积累和类固醇生成是偶联过程的假设。牛肾上腺质膜和牛肾上腺皮质细胞对促肾上腺皮质激素类似物的不同行为表明,使用环化酶测定的结构 - 功能研究可能无法反映完整肾上腺或从中衍生的细胞制剂中发生的事件。